Advertisement

A Nonlethal Murine Cutaneous Model of Invasive Aspergillosis

  • Ronen Ben-AmiEmail author
  • Dimitrios P. Kontoyiannis
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 845)

Abstract

Cutaneous models allow researchers to dynamically monitor infection by visually determining changes in skin lesion dimensions over time. We present a nonlethal cutaneous model of invasive aspergillosis (IA) in nude BALB/c mice and describe its use to determine altered virulence in Aspergillus strains and response to antifungal drugs. In addition, as an example of the versatility of this model, we show how the cutaneous model can be used to assess the effect of IA on angiogenesis in vivo.

Key words

Aspergillosis Cutaneous Model Virulence Drug Angiogenesis 

References

  1. 1.
    Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1–10.PubMedCrossRefGoogle Scholar
  2. 2.
    Bunce C, Wheeler L, Reed G, Musser J, Barg N. Murine model of cutaneous infection with gram-positive cocci. Infect Immun 1992;60:2636–40.PubMedGoogle Scholar
  3. 3.
    Burgos A, Zaoutis TE, Dvorak CC, et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics 2008;121:e1286–e94.PubMedCrossRefGoogle Scholar
  4. 4.
    Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000;79:250–60.CrossRefGoogle Scholar
  5. 5.
    Bio-Rad PlateliaTM Apergillus EIA package insert. 2010.Google Scholar
  6. 6.
    Keller NP, Turner G, Bennett JW. Fungal secondary metabolism - from biochemistry to genomics. Nat Rev Microbiol 2005;3:937–47.PubMedCrossRefGoogle Scholar
  7. 7.
    McDonagh A, Fedorova ND, Crabtree J, et al. Sub-telomere directed gene expression during initiation of invasive aspergillosis. PLoS Pathog 2008;4:e1000154.PubMedCrossRefGoogle Scholar
  8. 8.
    Lewis RE, Wiederhold NP, Chi J, et al. Detection of gliotoxin in experimental and human aspergillosis. Infect Immun 2005;73:635–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Passaniti A, Taylor RM, Pili R, et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 1992;67:519–28.PubMedGoogle Scholar
  10. 10.
    Ben-Ami R, Lewis RE, Leventakos K, Kontoyiannis DP. Aspergillus fumigatus inhibits angiogenesis through the production of gliotoxin and other secondary metabolites. Blood 2009;114:5393–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Ben-Ami R, Lewis RE, Leventakos K, Latge JP, Kontoyiannis DP. Cutaneous model of invasive aspergillosis. Antimicrob Agents Chemother 2010;54:1848–54.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Infectious Disease UnitTel Aviv Sourasky Medical CenterTel AvivIsrael
  2. 2.The University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations